A Randomized, Multiple Dose Study to Assess the Pharmacokinetics and Pharmacodynamics of IPX203 in Subjects With Advanced Parkinson's Disease
Latest Information Update: 07 Jun 2022
At a glance
- Drugs Levodopa/carbidopa (Primary) ; Levodopa/carbidopa
- Indications Parkinson's disease
- Focus Therapeutic Use
- Sponsors IMPAX Laboratories
- 12 Jul 2019 Primary endpoint (Percentage off time during waking hours) has been met, according to the results published in the Clinical Neuropharmacology
- 12 Jul 2019 Results published in the Clinical Neuropharmacology
- 06 Sep 2017 Status changed from active, no longer recruiting to completed.